IFRX Jumps on 2026 Trial Hype, But $1.00 Remains Out of Reach

InflaRx (Nasdaq: IFRX) Stock News

InflaRx (Nasdaq: IFRX) has made a sharp move in pre-market trading, with the stock jumping more than 8% to trade near $0.99, marking one of the largest single-day moves in a volatile micro-cap sector. That said, the broader Nasdaq and S&P 500 futures are drifting lower, adding context to what’s shaping as a stock-specific event.

Still, the rise in IFRX is not a market-wide rally. It’s a distinct move driven by a blend of product-related catalysts and regulatory uncertainty. For now, the stock looks like it’s breaking free from a prolonged range-bound pattern — at least temporarily.

Why Is IFRX Stock Rising in Pre-Market?

The sharp upward move is largely attributed to InflaRx’s announcement that it will present Phase 3 trial results for vilobelimab at the American Academy of Dermatology (AAD) annual meeting in 2026. In practice, such a development could enhance the drug’s visibility and therapeutic potential, especially if the data is encouraging.

That said, the catalyst is still a couple of months away, and the pre-market reaction is speculative. Even so, the stock has been under pressure for most of this year due to regulatory concerns, including a recent Nasdaq notice that its share price has been below the $1.00 minimum requirement for over 30 consecutive trading days.

Crucially, the market appears to be interpreting the AAD presentation as a potential turning point. At the end of the day, any meaningful data readout from a Phase 3 trial is seen as a high-impact event — and for a small-cap biotech like InflaRx, that can be a lifeline.

IFRX Support and Resistance Levels

From a technical perspective, the stock is trading just below $1.00, which appears to be a key psychological level. This level also aligns with the 20-day high and could serve as immediate resistance. On the flip side, the 20-day low of $0.8285 and the 50-day moving average at $0.95 are critical support areas to watch.

Still, the current price action is more indicative of a retesting of range boundaries than a breakout. The RSI at 54.8 and the lack of significant volume amplification suggest the move is more speculative than a broad-based conviction trade.

At this point, the key question is whether the move will hold or reverse — especially with the stock currently near the top end of its 60-day range. To put it clearly, the next few days could determine whether this is a short-term spike or the start of a more sustained rally.

The bottom line: Investors should keep a close eye on the $1.00 level for confirmation of strength and on the $0.92–$0.95 range for signs of support. Until then, the stock remains a high-volatility name with a mix of upside potential and regulatory headwinds to navigate.